Omeros Logo     Print Page  |  Close Window

Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

 
Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$22.03
Change (%) Stock is Down 0.45 (2.00%)
Volume528,038
Data as of 08/18/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
DateTitle  
08/15/17Omeros Announces Pricing of Public Offering of Common Stock
SEATTLE--(BUSINESS WIRE)--Aug. 15, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, announced today the pricing of its previously announced underwritten public offering of 3,000,... 
 Printer Friendly Version
08/14/17Omeros Announces Public Offering of Common Stock
SEATTLE--(BUSINESS WIRE)--Aug. 14, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced that it has commenced a registered underwritten public offering of 3,000,000 s... 
 Printer Friendly Version
08/14/17Omeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721
– Sustained Proteinuria Reduction and GFR Improvement in up to One-Year Follow-up Data – SEATTLE--(BUSINESS WIRE)--Aug. 14, 2017-- Omeros Corporation (NASDAQ: OMER) today announced additional follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 in the Phase 2 clinical trial of glomerulonephropathy. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine prot... 
 Printer Friendly Version
08/10/17Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Aug. 10, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will ... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2016 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.